Get the Stockscreener App
1.39
0.00%
0.00
Pmv Pharmaceuticals Inc stock is traded at $1.39, with a volume of 175.27K.
It is up +0.00% in the last 24 hours and up +4.51% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
See More
Previous Close:
$1.39
Open:
$1.39
24h Volume:
175.27K
Relative Volume:
0.29
Market Cap:
$74.13M
Revenue:
-
Net Income/Loss:
$-77.74M
P/E Ratio:
-0.9396
EPS:
-1.4793
Net Cash Flow:
$-73.61M
1W Performance:
-3.47%
1M Performance:
+4.51%
6M Performance:
-1.42%
1Y Performance:
+39.00%
1-Day Range:
$1.36
$1.39
1-Week Range:
$1.36
$1.488
52-Week Range:
$0.81
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.39 | 74.13M | 0 | -77.74M | -73.61M | -1.4793 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
PMV Pharmaceuticals (PMVP) to Release Earnings on Friday - MarketBeat
PMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84 - MSN
Short Interest in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Increases By 48.3% - MarketBeat
PMV Pharmaceuticals (PMVP) posts narrower than expected Q4 2025 loss, shares rise 1.37 percent in today's trading.Deceleration Risk - Newser
Is PMV Pharmaceuticals (PMVP) stock priced below intrinsic value (Institutional Demand) 2026-04-22Social Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
PMV Pharmaceuticals names Laurie Stelzer as board chair - Investing.com
PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed - TipRanks
PMV Pharmaceuticals names Laurie Stelzer as board chair By Investing.com - Investing.com Canada
[ARS] PMV Pharmaceuticals, Inc. SEC Filing - Stock Titan
PMV Pharmaceuticals Announces Board Chair Transition - Weekly Voice
The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform - Weekly Voice
As PMV nears a 2027 drug filing, its board chair changes hands - Stock Titan
Board shifts and pay vote in PMV Pharmaceuticals (NASDAQ: PMVP) 2026 proxy - Stock Titan
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth? - Yahoo Finance
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
PMV Pharmaceuticals (NASDAQ:PMVP) Stock Rating Upgraded by Evercore - MarketBeat
PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI - TipRanks
Stock List: Research Stocks from Around the World - GuruFocus
GUTS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is PMV Pharmaceuticals (PMVP) Stock Breaking Resistance | Price at $1.29, Down 0.77%Social Trading - Newser
Energy Moves: Will PMV Pharmaceuticals Inc outperform its industry peers2026 Momentum & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Dividend Watch: Is PMV Pharmaceuticals Inc exposed to currency risksQuarterly Earnings Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Quarterly Recap: Is Edgewell Personal Care Company forming bullish engulfing patternsIPO Watch & Growth Focused Entry Reports - baoquankhu1.vn
PLRX PE Ratio & Valuation, Is PLRX Overvalued - Intellectia AI
PMVP Stock Analysis: PMV Pharmaceuticals Inc Biotech Performance At 1.34 Price - Cổng thông tin điện tử tỉnh Lào Cai
Cantargia AB (7V3.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
PMVP SEC FilingsPmv Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Large Growth in Short Interest - MarketBeat
Aug Closing: Is PMV Pharmaceuticals Inc exposed to currency risks2026 Market Sentiment & Target Return Focused Stock Picks - baoquankhu1.vn
ICCC PE Ratio & Valuation, Is ICCC Overvalued - Intellectia AI
Why EXEL stock attracts strong analyst attention - baoquankhu1.vn
Analyst Upgrade: Is PMV Pharmaceuticals Inc benefiting from interest rate changesInflation Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Complete List of HealthcareBiotechnologyBiotechnology Stocks - GuruFocus
PMV Pharmaceuticals Insider Sellers Vindicated After 11% Drop - simplywall.st
Aug Swings: Is PMV Pharmaceuticals Inc exposed to currency risksDip Buying & Low Volatility Stock Recommendations - baoquankhu1.vn
US Market Wrap: Is PMV Pharmaceuticals Inc a potential multi bagger2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update - MarketBeat
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology - TipRanks
PMV Pharmaceuticals (PMVP) CFO receives 240,000-share stock option grant - Stock Titan
COO at PMV Pharmaceuticals (NASDAQ: PMVP) awarded 319,270 options - Stock Titan
PMV Pharmaceuticals (PMVP) awards 303,310 stock options to Chief Development Officer - Stock Titan
PMV Pharmaceuticals (PMVP) awards CEO 744,960 employee stock options - Stock Titan
PMV Pharmaceuticals (NASDAQ:PMVP) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Trend Recap: Does TriNet Group Inc have pricing powerEarnings Overview Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
PMV Pharmaceuticals, Inc.Common Stock (NQ: PMVP - The Chronicle-Journal
Risk On: Whats the outlook for PMV Pharmaceuticals Incs sectorWeekly Trend Report & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PMVP Reports Positive Phase 2 Results, Eyes 2027 NDA Submission - GuruFocus
PMV Pharma (PMVP) Reports Decline in Cash Reserves by Year-End 2 - GuruFocus
PMV Pharmaceuticals Reports Progress in PYNNACLE Trial of Rezatapopt for Ovarian Cancer and Announces Orphan Drug Designation from FDA - Quiver Quantitative
PMV Pharmaceuticals 10-K: Revenue $0, EPS $(1.48) — FY2025 results - TradingView
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):